Baranova D. S., Shamelashvili K. L.

NEW HORIZONS IN NEPHROPROTECTION: MECHANISMS AND CLINICAL APPLICATIONS OF SGLT2 INHIBITORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF CHRONIC KIDNEY DISEASE

---

Show/Download

About the author:

Baranova D. S., Shamelashvili K. L.

Heading:

MODERN ACHIEVEMENTS OF MEDICINE

Type of article:

Scientific article

Annotation:

Chronic kidney disease (CKD) remains a significant public health challenge, as it is associated with rapid progression and a substantially increased cardiovascular risk. Recent advances highlight the nephroprotective potential of sodium–glucose cotransporter-2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRAs), with finerenone being the most extensively studied representative of the latter class. This article summarizes the mechanisms of action of SGLT2i and MRAs and analyzes their clinical efficacy in slowing CKD progression, reducing albuminuria, and lowering cardiovascular risk. Particular emphasis is placed on the prospects of combination therapy, which may provide a multifaceted organ-protective effect due to complementary mechanisms of action.

Tags:

Bibliography:

1. Theodorakopoulou M, Sarafidis P. SGLT2 inhibitors and finerenone in non‑diabetic CKD: a step into the (near) future? Clinical Kidney Journal. 2024;17(1):sfad272. DOI: 10.1093/ckj/sfad272.
2. Hallow KM, Greasley PJ, Helmlinger G, Chu L, Heerspink HJ, Boulton DW. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model‑based analysis of clinical data. Am J Physiol Renal Physiol. 2018;315(5):F1295‑F1306. DOI: 10.1152/ajprenal.00202.2018.
3. Lutay Y, Parkhomenko A. Mechanisms of renoprotective action of sodium‑glucose cotransporter‑2 inhibitors (gliflozins): a clinician’s view. Int J Endocrinol. 2023;19:39‑44. DOI: 10.22141/2224‑0721.19.1.2023.1240.
4. Padda IS, Mahtani AU, Parmar M. Sodium‑Glucose Transport 2 (SGLT2) Inhibitors. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576405/.
5. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295‑2306. DOI: 10.1056/NEJMoa1811744.
6. Heerspink HJL, Stefánsson BV, Correa‑Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney dis‑ ease. N Engl J Med. 2020;383(15):1436‑1446. DOI: 10.1056/NEJMoa2024816.
7. The EMPA‑KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117‑127. DOI: 10.1056/NEJMoa2204233.
8. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252‑2263. DOI: 10.1056/NEJMoa2110956.
9. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219‑2229. DOI: 10.1056/NEJMoa2025845.
10. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474‑484. DOI: 10.1093/eurheartj/ehab777.

Publication of the article:

«Bulletin of problems biology and medicine», 2025 Issue 4, 179, addition, 101-103 pages, index UDC 616.61-008.61:615.275:615.252

DOI:

10.29254/2523-4110-2025-4-179/addition-101-103